Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20847152 | 0.83 | HPGD (0.41) | HPGDP2RX3MEN1KMT2AALDH1A1 | |
| SCHEMBL7058025 | 0.82 | HPGD (0.62) | HPGDMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL20847153 | 0.82 | ALDH1A1 (0.51) | HPGDMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL145903 | 0.74 | KDM4C (0.44) | P2RX3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL16634668 | 0.73 | KMT2A (0.45) | HPGDMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5422297 | 0.72 | KDM4C (0.51) | P2RX3MEN1KMT2AKDM4CRAB9A | |
| SCHEMBL377967 | 0.72 | KDM4C (0.44) | P2RX3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5429878 | 0.71 | KDM4C (0.49) | P2RX3MEN1KMT2AALDH1A1KDM4C | |
| SCHEMBL18045760 | 0.70 | MEN1 (0.47) | P2RX3MEN1KMT2AKDM4CRAB9A | |
| SCHEMBL3744988 | 0.69 | MEN1 (0.49) | P2RX3MEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200216471-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2019060365-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | HPGD 4277/4885P2RX3 4856/4885MEN1 2/4885 |
| US-20200216471-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | HPGD 4277/4885P2RX3 4856/4885MEN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.